Biological
Adagloxad simolenin clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 2
OBI Pharma, Inc (1) · Chang Gung Memorial Hospital (1) · Mackay Memorial Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses adagloxad simolenin is read from its arms, and is right about nine times in ten.
Testing it · 3
- Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT GenotypeTerminatedPhase 2Chang Gung Memorial HospitalNCT03608878Written as adagloxad simolenin/OBI-821
- Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer SubjectsCompletedPhase 2OBI Pharma, IncNCT01516307Written as OPT-822/OPT-821(30 μg/100 μg)
- Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian CancerStatus unknownPhase 2Mackay Memorial HospitalNCT02132988Written as OPT-822/OPT-821
Codes
What other systems call adagloxad simolenin · ClinicalTrials.gg INT018116
- UNII (FDA) UCG949AA7ZADAGLOXAD SIMOLENINOne source FDA
- NCI Thesaurus C99766Adagloxad SimoleninOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UCG949AA7Z | ADAGLOXAD SIMOLENIN | One source FDA |
| NCI Thesaurus | C99766 | Adagloxad Simolenin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.